Findings from Foundation Policlinico University A Gemelli IRCCS Yields New Data on Smoothened Receptor Antagonists (Clinical Characteristics of an Italian Patient Population With Advanced Bcc and Real-life Evaluation of Hhi Safety and...).

Předmět:	HEDGEHOG signaling proteins
Zdroj:	Drug Week; 7/21/2023, p558-558, 1p
Abstrakt:	Keywords: Rome; Italy; Europe; Drugs and Therapies; Hedgehog Pathway Inhibitor; Smoothened Receptor Antagonists EN Rome Italy Europe Drugs and Therapies Hedgehog Pathway Inhibitor Smoothened Receptor Antagonists 558 558 1 07/17/23 20230721 NES 230721 2023 JUL 21 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Investigators publish new report on Drugs and Therapies - Smoothened Receptor Antagonists. Systemic therapy with hedgehog pathway inhibitors (HHI) changed the treatment landscape for this complex patient population." For HHI safety assessment, therapy-related adverse events (AEs) were reported and graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. we enrolled 178 patients under treatment with HHI: 126 (70.8%) and 52 patients (29.2%) received sonidegib and vismodegib, respectively. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu